A new study published in the March 3 issue of the Journal of the American Medical Association (JAMA) finds that a medical need-based donor lung allocation protocol has been associated with better graft survival than single-lung transplantation procedures in persons afflicted with idiopathic pulmonary fibrosis (IPF). The…
Idiopathic Pulmonary Fibrosis Outcomes Improved With Need-Based Allocation And Double Lung Transplants
(Back row, left to right) Broadway Belts for PFF! cast members, Julia Murney, Randy Graff, Julie Halston, Erich Bergen, Zakiya Young, Betsy Wolfe (Front row, left to right) Bobby Creighton, Annaleigh Ashford, Santino Fontana. The Tony award-winning cast performed at the Broadway Belts for PFF! fundraiser to…
Dr. Thomas Kuerner at Nippon Boehringer Ingelheim Co., Ltd. in Japan published a review regarding the critical rules and requirements for global clinical trials in rare lung diseases such as pulmonary fibrosis from a sponsor’s perspective. The review was published in the journal…
Researchers from Shanghai Jiao Tong University in China published in the journal BioMed Research International their findings on the mechanism behind acute lung injury and pulmonary fibrosis observed after poisoning with the chemical paraquat. The study is entitled “DNaseI Protects…
Galapagos NV recently announced that GLPG1690, its molecule to address pulmonary diseases such as pulmonary fibrosis, has demonstrated target engagement and a very good safety profile, with Phase 1 results showing favorable drug properties. Galapagos is now advancing GLPG1690 with partner Janssen Pharmaceutica NV. Pulmonary fibrosis…
Results from a recent survey called EXPLORE IPF showed that people with idiopathic pulmonary fibrosis (IPF) have a lack of understanding of their disease, experience significant emotional difficulties, and report the need for more support and care resources to help them deal with their condition. “These survey findings remind me of…
Researchers from the Nippon Medical School in Tokyo published a report in the journal Respiratory Medicine Case Reports highlighting an individual case study of a patient with pulmonary hypertension associated with idiopathic pulmonary fibrosis that had a good overall improvement after treatment with bosentan. The prevalence…
MediciNova, Inc. a biopharmaceutical company targeting the development of novel small-molecule treatments for conditions with unmet medical needs, recently announced that the U.S. Food and Drug Administration (FDA) approved their protocol for a new clinical trial of MN-001 (under the name tipelukast) as a potential therapeutic for patients with…
ProMetic Life Sciences Inc. reported that their investigational PBI-4050 drug, the firm’s leading anti-fibrotic candidate to address idiopathic pulmonary fibrosis (IPF), was approved to begin clinical trials following CTA clearance by Health Canada. IPF is a devastating, chronic and fatal disease that is characterized by a progressive decline in lung function. It is…
Mutations in telomere genes may cause pulmonary fibrosis, emphysema and impact life expectancy, according to new research results. Telomeres are found at the end of chromosomes, where they act like a protective tip. When cells divide, telomeres shorten. Over the lifespan, with multiple cell division and aging, telomeres get shorter. Eventually telomeres become so short…
